Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Toby M Maher

Showing results (191-200 of 391) with videos related to

Pageof 40
Sort By:
The European Respiratory Journal|March 9, 2019
Patient-reported distress can aid clinical decision-making in idiopathic pulmonary fibrosis: analysis of the PROFILE cohortIain Stewart, Tricia McKeever, Rebecca Braybrooke, et al.
The European Respiratory Journal|November 30, 2018
Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort studyClaire M Nolan, Matthew Maddocks, Toby M Maher, et al.
Respirology (Carlton, Vic.)|November 30, 2013
Rituximab in severe, treatment-refractory interstitial lung diseaseGregory J Keir, Toby M Maher, Damien Ming, et al.
Rheumatology (Oxford, England)|September 16, 2022
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trialChristopher P Denton, Nicole S Goh, Stephen M Humphries, et al.
The European Respiratory Journal|October 3, 2020
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosisToby M Maher, Ulrich Costabel, Marilyn K Glassberg, et al.
The Lancet. Respiratory Medicine|July 22, 2019
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled studyToby M Maher, Susanne Stowasser, Yasuhiko Nishioka, et al.
Chest|May 15, 2023
Nocturnal Hypoxemia Associates With Symptom Progression and Mortality in Patients With Progressive Fibrotic Interstitial Lung DiseaseKatherine J Myall, Alex G West, Jennifer L Martinovic, et al.
ERJ Open Research|October 27, 2018
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT studyVincent Cottin, Dirk Koschel, Andreas Günther, et al.
Thorax|September 9, 2017
Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: a prospective studyClaire M Nolan, Veronica Delogu, Matthew Maddocks, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 14, 2024
[<sup>18</sup>F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung DiseasesJoanna C Porter, Balaji Ganeshan, Thida Win, et al.
Pageof 40

Showing results (191-200 of 391) with videos related to

Sort By:
Pageof 40
The European Respiratory Journal|March 9, 2019
Patient-reported distress can aid clinical decision-making in idiopathic pulmonary fibrosis: analysis of the PROFILE cohortIain Stewart, Tricia McKeever, Rebecca Braybrooke, et al.
The European Respiratory Journal|November 30, 2018
Gait speed and prognosis in patients with idiopathic pulmonary fibrosis: a prospective cohort studyClaire M Nolan, Matthew Maddocks, Toby M Maher, et al.
Respirology (Carlton, Vic.)|November 30, 2013
Rituximab in severe, treatment-refractory interstitial lung diseaseGregory J Keir, Toby M Maher, Damien Ming, et al.
Rheumatology (Oxford, England)|September 16, 2022
Extent of fibrosis and lung function decline in patients with systemic sclerosis and interstitial lung disease: data from the SENSCIS trialChristopher P Denton, Nicole S Goh, Stephen M Humphries, et al.
The European Respiratory Journal|October 3, 2020
Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosisToby M Maher, Ulrich Costabel, Marilyn K Glassberg, et al.
The Lancet. Respiratory Medicine|July 22, 2019
Biomarkers of extracellular matrix turnover in patients with idiopathic pulmonary fibrosis given nintedanib (INMARK study): a randomised, placebo-controlled studyToby M Maher, Susanne Stowasser, Yasuhiko Nishioka, et al.
Chest|May 15, 2023
Nocturnal Hypoxemia Associates With Symptom Progression and Mortality in Patients With Progressive Fibrotic Interstitial Lung DiseaseKatherine J Myall, Alex G West, Jennifer L Martinovic, et al.
ERJ Open Research|October 27, 2018
Long-term safety of pirfenidone: results of the prospective, observational PASSPORT studyVincent Cottin, Dirk Koschel, Andreas Günther, et al.
Thorax|September 9, 2017
Validity, responsiveness and minimum clinically important difference of the incremental shuttle walk in idiopathic pulmonary fibrosis: a prospective studyClaire M Nolan, Veronica Delogu, Matthew Maddocks, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|March 14, 2024
[<sup>18</sup>F]FDG PET/CT Signal Correlates with Neoangiogenesis Markers in Patients with Fibrotic Interstitial Lung Disease Who Underwent Lung Biopsy: Implication for the Use of PET/CT in Diffuse Lung DiseasesJoanna C Porter, Balaji Ganeshan, Thida Win, et al.
Pageof 40